menu
    • menu

    Company profile for Ascletis Pharma

    NEW Drugs in Dev: 24
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ascletis’ mission：Innovative cures liberate life to the fullest. Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Ascletis’ vision ：To become the most innovative world-class biomedical company. Led by a management team with deep expertise and a proven track record, we have developed an integrated platfor...
    Ascletis’ mission：Innovative cures liberate life to the fullest. Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Ascletis’ vision ：To become the most innovative world-class biomedical company. Led by a management team with deep expertise and a proven track record, we have developed an integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ascletis PharmaChina Flag
    Country
    Country
    China
    Address
    Address
    1785 Jianghai Rd, Bldg No.1, Ste 804, Binjiang District, Hangzhou, Zhejiang
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ascletis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH
    Sagimet Announces Positive 52-Wk Denifanstat Data in Severe MASH

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230125/0/en/Sagimet-Announces-Positive-52-Week-Data-from-License-Partner-Ascletis-Open-Label-Phase-3-Clinical-Trial-Evaluating-the-Long-Term-Safety-of-ASC40-Denifanstat-Tablets-in-Patients-wit.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Ascletis Reports Positive Phase III Results For Denifanstat
    Ascletis Reports Positive Phase III Results For Denifanstat

    29 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-its-phase-iii-open-label-study-of-denifanstat-asc40-a-first-in-class-once-daily-oral-fasn-inhibitor-for-acne-302673868.html

    PR NEWSWIRE
    29 Jan 2026
    Share Share
    Ascletis to Develop ASC37 Triple Agonist
    Ascletis to Develop ASC37 Triple Agonist

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-selects-a-next-generation-once-monthly-subcutaneously-administered-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302665194.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    FDA Clears IND for Ascletis' Oral GLP-1 ASC30 Phase II Trial
    FDA Clears IND for Ascletis' Oral GLP-1 ASC30 Phase II Trial

    04 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-us-fda-ind-clearance-for-13-week-phase-ii-study-of-its-oral-small-molecule-glp-1-asc30-in-participants-with-diabetes-302652107.html

    PR NEWSWIRE
    04 Jan 2026
    Share Share
    Ascletis Reports Positive U.S. Phase I Results For ASC50, IL-17
    Ascletis Reports Positive U.S. Phase I Results For ASC50, IL-17

    15 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-i-study-of-asc50-a-potential-best-in-class-oral-small-molecule-il-17-inhibitor-302641987.html

    PR NEWSWIRE
    15 Dec 2025
    Share Share
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne
    Ascletis Accepts Denifanstat NDA For Moderate To Severe Acne

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203051/0/en/Sagimet-s-License-Partner-Ascletis-Announced-Acceptance-of-New-Drug-Application-for-Denifanstat-for-the-Treatment-of-Moderate-to-Severe-Acne-by-China-s-National-Medical-Products-Ad.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search